MiNK Therapeutics (INKT) Common Equity (2020 - 2026)
MiNK Therapeutics (INKT) posted Common Equity of -$12.7 million for Q1 2026, up 10.84% sequentially from -$14.2 million in Q4 2025, and up 41.79% YoY from -$8.9 million in Q1 2025.
MiNK Therapeutics (INKT) Common Equity (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Common Equity for 7 years, with the latest figure at -$12.7 million in Q1 2026.
- Quarterly Common Equity rose 41.79% year-over-year to -$12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.7 million (up 41.79% YoY) and the FY2025 annual result came in at -$14.2 million, up 27.36% from the prior year.
- Common Equity grew to -$12.7 million in Q1 2026 per INKT's latest filing, from -$14.2 million in the prior quarter.
- Over five years, Common Equity peaked at $17.3 million in Q1 2022 and troughed at -$25.2 million in Q2 2025.
- A 5-year average of -$10.0 million and a median of -$13.6 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity jumped 130.32% in 2022, then tumbled 4399.21% in 2023.
- Over 5 years, Common Equity stood at -$401303.0 in 2022, then sank by 4399.21% to -$18.1 million in 2023, then retreated by 8.48% to -$19.6 million in 2024, then grew by 27.36% to -$14.2 million in 2025, then climbed by 10.84% to -$12.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$12.7 million, -$14.2 million, and -$13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | MiNK Therapeutics | 57.77 Mn | 57.77 Mn | - | -14.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.03 Mn |
| Mar 31, 2026 | -12.69 Mn |
| Dec 31, 2025 | -14.23 Mn |
| Sep 30, 2025 | -13.51 Mn |
| Jun 30, 2025 | -25.19 Mn |
| Mar 31, 2025 | -21.79 Mn |
| Dec 31, 2024 | -19.59 Mn |
| Sep 30, 2024 | -17.55 Mn |
| Jun 30, 2024 | -16.58 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Dec 31, 2023 | -18.06 Mn |
| Sep 30, 2023 | -13.58 Mn |
| Jun 30, 2023 | -9.50 Mn |
| Mar 31, 2023 | -4.48 Mn |
| Dec 31, 2022 | -401,303.00 |
| Sep 30, 2022 | 6.76 Mn |
| Jun 30, 2022 | 13.69 Mn |
| Mar 31, 2022 | 17.31 Mn |
| Dec 31, 2021 | 23.78 Mn |
| Sep 30, 2021 | -76.51 Mn |